Jeil Pharmaceutical Co Ltd (271980) - Total Assets
Based on the latest financial reports, Jeil Pharmaceutical Co Ltd (271980) holds total assets worth ₩526.12 Billion KRW (≈ $356.54 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jeil Pharmaceutical Co Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Jeil Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 271980 market cap for the company's overall valuation and market capitalisation.
Jeil Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Jeil Pharmaceutical Co Ltd's total assets of ₩526.12 Billion consist of 61.0% current assets and 39.0% non-current assets. Review 271980 total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 9.6% |
| Accounts Receivable | ₩136.85 Billion | 26.8% |
| Inventory | ₩104.47 Billion | 20.5% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩15.44 Billion | 3.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Jeil Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 271980 share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jeil Pharmaceutical Co Ltd's current assets represent 61.0% of total assets in 2025, a decrease from 72.2% in 2017.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2025, up from 3.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 26.8% of total assets.
Jeil Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jeil Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Jeil Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.33 | 1.26 | 1.33 |
| Quick Ratio | 0.92 | 0.85 | 0.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩81.81 Billion | ₩61.87 Billion | ₩76.91 Billion |
Jeil Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jeil Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.75 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | ₩510.57 Billion |
| Market Capitalization | $99.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jeil Pharmaceutical Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Jeil Pharmaceutical Co Ltd's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jeil Pharmaceutical Co Ltd (2017–2025)
The table below shows the annual total assets of Jeil Pharmaceutical Co Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩510.57 Billion ≈ $346.01 Million |
-2.88% |
| 2024-12-31 | ₩525.70 Billion ≈ $356.26 Million |
+7.87% |
| 2023-12-31 | ₩487.33 Billion ≈ $330.25 Million |
+6.66% |
| 2022-12-31 | ₩456.89 Billion ≈ $309.63 Million |
+7.13% |
| 2021-12-31 | ₩426.49 Billion ≈ $289.02 Million |
+4.11% |
| 2020-12-31 | ₩409.66 Billion ≈ $277.62 Million |
+2.01% |
| 2019-12-31 | ₩401.59 Billion ≈ $272.15 Million |
-0.33% |
| 2018-12-31 | ₩402.90 Billion ≈ $273.04 Million |
-2.62% |
| 2017-12-31 | ₩413.73 Billion ≈ $280.38 Million |
-- |
About Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more